APO Research
Talk to an analyst

APO RESEARCH · REPORT

Soliris (Eculizumab)

Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.

Selected research

Market Outlook & Growth Opportunities

Global Soliris (Eculizumab) Market Outlook and Growth Opportunities 2026

19 December 2025197 pages

Choose your research edition.

Industry ResearchSoliris (Eculizumab) Industry Research Report 2026104 pages · $2,950 USDIndustry Growth & TrendsGlobal Soliris (Eculizumab) Industry Growth and Trends Forecast to 203263 pages · $3,450 USDMarket StructureGlobal Soliris (Eculizumab) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Soliris (Eculizumab) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Soliris (Eculizumab) Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.

In Asia-Pacific, Japan is the largest Soliris (Eculizumab) market with about 32% market share. China is follower, accounting for about 25% market share.The key manufacturers are Alexion etc.

This report provides an overview of the global Soliris (Eculizumab) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Soliris (Eculizumab) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Soliris (Eculizumab) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Soliris (Eculizumab) market.

Soliris (Eculizumab) Segment by Company

Alexion

Soliris (Eculizumab) Segment by Type

Plasma Exchange

Plasma Infusion

Soliris (Eculizumab) Segment by Application

PNH

aHUS

Others

Soliris (Eculizumab) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Soliris (Eculizumab) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Soliris (Eculizumab) key companies, revenue, market share, and recent developments.

3. To split the Soliris (Eculizumab) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Soliris (Eculizumab) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Soliris (Eculizumab) significant trends, drivers, influence factors in global and regions.

6. To analyze Soliris (Eculizumab) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Soliris (Eculizumab) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Soliris (Eculizumab) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Soliris (Eculizumab).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Soliris (Eculizumab) industry.

Chapter 3: Detailed analysis of Soliris (Eculizumab) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Soliris (Eculizumab) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Soliris (Eculizumab) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Soliris (Eculizumab) Industry Trends Table 2. Soliris (Eculizumab) Industry Drivers Table 3. Soliris (Eculizumab) Industry Opportunities and Challenges Table 4. Soliris (Eculizumab) Industry Restraints Table 5. Global Soliris (Eculizumab) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Soliris (Eculizumab) Revenue Share by Company (2021-2026) Table 7. Global Soliris (Eculizumab) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Soliris (Eculizumab) Key Company Manufacturing Base & Headquarters Table 9. Global Soliris (Eculizumab) Company, Product Type & Application Table 10. Global Soliris (Eculizumab) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Soliris (Eculizumab) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Plasma Exchange Table 15. Significant Companies of Plasma Infusion Table 16. Global Soliris (Eculizumab) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Soliris (Eculizumab) Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Soliris (Eculizumab) Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Soliris (Eculizumab) Sales Value Share by Type (2021-2026) Table 20. Global Soliris (Eculizumab) Sales Value Share by Type (2027-2032) Table 21. Significant Companies of PNH Table 22. Significant Companies of aHUS Table 23. Significant Companies of Others Table 24. Global Soliris (Eculizumab) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Soliris (Eculizumab) Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Soliris (Eculizumab) Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Soliris (Eculizumab) Sales Value Share by Application (2021-2026) Table 28. Global Soliris (Eculizumab) Sales Value Share by Application (2027-2032) Table 29. Global Soliris (Eculizumab) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Soliris (Eculizumab) Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Soliris (Eculizumab) Sales Value Share by Region (2021-2026) Table 32. Global Soliris (Eculizumab) Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Soliris (Eculizumab) Sales Value Share by Region (2027-2032) Table 34. Global Soliris (Eculizumab) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Soliris (Eculizumab) Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Soliris (Eculizumab) Sales Value Market Share by Country (2021-2026) Table 37. Global Soliris (Eculizumab) Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Soliris (Eculizumab) Sales Value Market Share by Country (2027-2032) Table 39. Alexion Company Information Table 40. Alexion Business Overview Table 41. Alexion Soliris (Eculizumab) Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Alexion Soliris (Eculizumab) Product Portfolio Table 43. Alexion Recent Development Table 44. Research Programs/Design for This Report Table 45. Authors List of This Report Table 46. Secondary Sources Table 47. Primary Sources List of Figures Figure 1. Soliris (Eculizumab) Product Image Figure 2. Global Soliris (Eculizumab) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Soliris (Eculizumab) Market Size (2021-2032) & (US$ Million) Figure 4. Global Soliris (Eculizumab) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Plasma Exchange Image Figure 8. Plasma Infusion Image Figure 9. Global Soliris (Eculizumab) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Soliris (Eculizumab) Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Soliris (Eculizumab) Sales Value Share by Type (2021-2032) Figure 12. PNH Image Figure 13. aHUS Image Figure 14. Others Image Figure 15. Global Soliris (Eculizumab) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Soliris (Eculizumab) Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Soliris (Eculizumab) Sales Value Share by Application (2021-2032) Figure 18. Global Soliris (Eculizumab) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Soliris (Eculizumab) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Soliris (Eculizumab) Sales Value (2021-2032) & (US$ Million) Figure 21. North America Soliris (Eculizumab) Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Soliris (Eculizumab) Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Soliris (Eculizumab) Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Soliris (Eculizumab) Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Soliris (Eculizumab) Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Soliris (Eculizumab) Sales Value (2021-2032) & (US$ Million) Figure 27. South America Soliris (Eculizumab) Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Soliris (Eculizumab) Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Soliris (Eculizumab) Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Soliris (Eculizumab) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Plasma Exchange
  • Plasma Infusion
Applications
  • PNH
  • aHUS
  • Others
Companies covered
  • Alexion

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Soliris (Eculizumab) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Soliris (Eculizumab) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Soliris (Eculizumab) Market Dynamics
  1. 2.1 Soliris (Eculizumab) Industry Trends
  2. 2.2 Soliris (Eculizumab) Industry Drivers
  3. 2.3 Soliris (Eculizumab) Industry Opportunities and Challenges
  4. 2.4 Soliris (Eculizumab) Industry Restraints
3 Soliris (Eculizumab) Market by Company
  1. 3.1 Global Soliris (Eculizumab) Company Revenue Ranking in 2025
  2. 3.2 Global Soliris (Eculizumab) Revenue by Company (2021-2026)
  3. 3.3 Global Soliris (Eculizumab) Company Ranking (2024-2026)
  4. 3.4 Global Soliris (Eculizumab) Company Manufacturing Base and Headquarters
  5. 3.5 Global Soliris (Eculizumab) Company Product Type and Application
  6. 3.6 Global Soliris (Eculizumab) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Soliris (Eculizumab) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Soliris (Eculizumab) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Soliris (Eculizumab) Market by Type
  1. 4.1 Soliris (Eculizumab) Type Introduction
  2. 4.1.1 Plasma Exchange
  3. 4.1.2 Plasma Infusion
  4. 4.2 Global Soliris (Eculizumab) Sales Value by Type
  5. 4.2.1 Global Soliris (Eculizumab) Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Soliris (Eculizumab) Sales Value by Type (2021-2032)
  7. 4.2.3 Global Soliris (Eculizumab) Sales Value Share by Type (2021-2032)
5 Soliris (Eculizumab) Market by Application
  1. 5.1 Soliris (Eculizumab) Application Introduction
  2. 5.1.1 PNH
  3. 5.1.2 aHUS
  4. 5.1.3 Others
  5. 5.2 Global Soliris (Eculizumab) Sales Value by Application
  6. 5.2.1 Global Soliris (Eculizumab) Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Soliris (Eculizumab) Sales Value by Application (2021-2032)
  8. 5.2.3 Global Soliris (Eculizumab) Sales Value Share by Application (2021-2032)
6 Soliris (Eculizumab) Regional Value Analysis
  1. 6.1 Global Soliris (Eculizumab) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Soliris (Eculizumab) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Soliris (Eculizumab) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Soliris (Eculizumab) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Soliris (Eculizumab) Sales Value (2021-2032)
  7. 6.3.2 North America Soliris (Eculizumab) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Soliris (Eculizumab) Sales Value (2021-2032)
  10. 6.4.2 Europe Soliris (Eculizumab) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Soliris (Eculizumab) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Soliris (Eculizumab) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Soliris (Eculizumab) Sales Value (2021-2032)
  16. 6.6.2 South America Soliris (Eculizumab) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Soliris (Eculizumab) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Soliris (Eculizumab) Sales Value Share by Country, 2025 VS 2032
7 Soliris (Eculizumab) Country-level Value Analysis
  1. 7.1 Global Soliris (Eculizumab) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Soliris (Eculizumab) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Soliris (Eculizumab) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Soliris (Eculizumab) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Soliris (Eculizumab) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Soliris (Eculizumab) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Soliris (Eculizumab) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Alexion
  2. 8.1.1 Alexion Company Information
  3. 8.1.2 Alexion Business Overview
  4. 8.1.3 Alexion Soliris (Eculizumab) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Alexion Soliris (Eculizumab) Product Portfolio
  6. 8.1.5 Alexion Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst